RE:a dead end. Ahhhh....some real 'short' term thinking here and here's why you are so wrong....and why it's time to get with the program!
FDA approval will mean it can't be 'knocked' off for a period of 7 years and to the party that is not the 'sum of all their parts', I'm up over 25% having held CRDL for 2+ years now.
At this point I'm very happy with the ROR and its only going to get better and better!......
The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphan status”). For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDA’s implementing regulations at 21 CFR Part 316. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.
The purpose of the designation was to create financial incentives for companies to develop new drugs and biologics for rare diseases. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity [1].
GiveMeMoney wrote: CRDL's main medical will be knocked off within 1.5-2 years with a generic and it's cortical is a commodity that many will enter, with all the capacity on the continent, as well. it has no moat.
it's market is tiny. with respect to 'returns', if you would have invested whatever during the same amount of time that you've waited for 'THE POP' where would you have been with the winds in the past months in the market, with an awful lot less stress.
and you're still looking at a dead-end investment over the l/term.